IL-33 and the intestine: The good, the bad, and the inflammatory

Cytokine

Volumn 100, Issue , 2017, Pages 1-10

  Hodzic, Zerina ^a   Schill, Ellen Merrick ^b   Bolock, Alexa M ^b   Good, Misty ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammatory bowel disease; Interleukin 33; Intestinal immunity; Microbiome; T cells

Indexed keywords

IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 33; CYTOKINE; INTERLEUKIN 1;

ADAPTIVE IMMUNITY; CD8+ T LYMPHOCYTE; CROHN DISEASE; FIBROBLAST; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE; INTESTINE EPITHELIUM; INTESTINE FLORA; LYMPHOID CELL; MUCOSAL IMMUNITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL; ULCERATIVE COLITIS; ANIMAL; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY; MOUSE; PATHOPHYSIOLOGY;

ANIMALS; CYTOKINES; GASTROINTESTINAL MICROBIOME; HUMANS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-1; INTERLEUKIN-33; INTESTINAL MUCOSA; INTESTINES; MICE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS;

EID: 85021729895     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2017.06.017     Document Type: Review

References (132)

1. Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T.K., Zurawski, G., Moshrefi, M., Qin, J., Li, X., Gorman, D.M., Bazan, J.F., Kastelein, R.A., IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:5 (2005), 479–490.
2. Ali, S., The dual function cytokine IL-33 interacts with the transcription factor NF-kB to dampen NF-kB-stimulated gene transcription. J. Immunol. 187 (2011), 1609–1616.
3. Lohning, M., T1/ST2 is preferentially expressed on murine TH2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for TH2 effector function. Proc. Natl. Acad. Sci. USA 95 (1998), 6930–6935.
4. Liew, F.Y., Girard, J.P., Turnquist, H.R., Interleukin-33 in health and disease. Nat. Rev. Immunol. 16:11 (2016), 676–689.
5. Martin, N.T., Martin, M.U., Interleukin 33 is a guardian of barriers and a local alarmin. Nat. Immunol. 17:2 (2016), 122–131.
6. Kakkar, R., Lee, R.T., The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat. Rev. Drug. Discov. 7:10 (2008), 827–840.
7. Martin, M.U., Special aspects of interleukin-33 and the IL-33 receptor complex. Semin. Immunol. 25:6 (2013), 449–457.
8. Pichery, M., Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J. Immunol. 188 (2012), 3488–3495.
9. Moussion, C., Ortega, N., Girard, J.P., The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?. PLoS One, 3(10), 2008, e3331.
10. Lefrancais, E., IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc. Natl. Acad. Sci. USA 109 (2012), 1673–1678.
11. Lefrancais, E., Duval, A., Mirey, E., Roga, S., Espinosa, E., Cayrol, C., Girard, J.P., Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proceedings of the National Academy of Sciences of the United States of America 111:43 (2014), 15502–15507.
12. Carriere, V., Roussel, L., Ortega, N., Lacorre, D.A., Americh, L., Aguilar, L., Bouche, G., Girard, J.P., IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. USA 104:1 (2007), 282–287.
13. Roussel, L., Erard, M., Cayrol, C., Girard, J.P., Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A–H2B acidic pocket. EMBO Rep. 9:10 (2008), 1006–1012.
14. Kuchler, A.M., Pollheimer, J., Balogh, J., Sponheim, J., Manley, L., Sorensen, D.R., De Angelis, P.M., Scott, H., Haraldsen, G., Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am. J. Pathol. 173:4 (2008), 1229–1242.
15. Sundlisaeter, E., Edelmann, R.J., Hol, J., Sponheim, J., Kuchler, A.M., Weiss, M., Udalova, I.A., Midwood, K.S., Kasprzycka, M., Haraldsen, G., The alarmin IL-33 is a notch target in quiescent endothelial cells. Am. J. Pathol. 181:3 (2012), 1099–1111.
16. Baekkevold, E.S., Roussigné, M., Yamanaka, T., Johansen, F.-E., Jahnsen, F.L., Amalric, F., Brandtzaeg, P., Erard, M., Haraldsen, G., Girard, J.-P., Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am. J. Pathol. 163:1 (2003), 69–79.
17. Ali, S., Nguyen, D.Q., Falk, W., Martin, M.U., Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation. Biochem. Biophys. Res. Commun. 391:3 (2010), 1512–1516.
18. Kunisch, E., Chakilam, S., Gandesiri, M., Kinne, R.W., IL-33 regulates TNF-alpha dependent effects in synovial fibroblasts. Int. J. Mol. Med. 29:4 (2012), 530–540.
19. Oshio, T., Komine, M., Tsuda, H., Tominaga, S.I., Saito, H., Nakae, S., Ohtsuki, M., Nuclear expression of IL-33 in epidermal keratinocytes promotes wound healing in mice. J. Dermatol. Sci. 85:2 (2017), 106–114.
20. Ohno, T., Oboki, K., Kajiwara, N., Morii, E., Aozasa, K., Flavell, R.A., Okumura, K., Saito, H., Nakae, S., Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J. Immunol. 183:12 (2009), 7890–7897.
21. Bessa, J., Meyer, C.A., de Vera Mudry, M.C., Schlicht, S., Smith, S.H., Iglesias, A., Cote-Sierra, J., Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation. J. Autoimmun. 55 (2014), 33–41.
22. Lefrancais, E., Cayrol, C., Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members. Eur. Cytokine Netw. 23:4 (2012), 120–127.
23. Carta, S., Lavieri, R., Rubartelli, A., Different members of the IL-1 family come out in different ways: DAMPs vs. cytokines?. Front. Immunol., 4, 2013, 123.
24. Kaczmarek, A., Vandenabeele, P., Krysko, Dmitri V., Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 38:2 (2013), 209–223.
25. Camilleri, M., Madsen, K., Spiller, R., Van Meerveld, B.G., Verne, G.N., Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol. Motil.: Off. J. Eur. Gastr. Motil. Soc., 24, 2012.
26. Shimokawa, C., Kanaya, T., Hachisuka, M., Ishiwata, K., Hisaeda, H., Kurashima, Y., Kiyono, H., Yoshimoto, T., Kaisho, T., Ohno, H., Mast cells are crucial for induction of Group 2 innate lymphoid cells and clearance of helminth infections. Immunity 46:5 (2017), 863–874 e4.
27. Zhang, L., Lu, R., Zhao, G., Pflugfelder, S.C., Li, D.Q., TLR-mediated induction of pro-allergic cytokine IL-33 in ocular mucosal epithelium. Int. J. Biochem. Cell Biol. 43:9 (2011), 1383–1391.
28. Hudson, C.A., Christophi, G.P., Gruber, R.C., Wilmore, J.R., Lawrence, D.A., Massa, P.T., Induction of IL-33 expression and activity in central nervous system glia. J. Leukoc. Biol. 84:3 (2008), 631–643.
29. Kakkar, R., Hei, H., Dobner, S., Lee, R.T., Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J. Biol. Chem. 287:9 (2012), 6941–6948.
30. Zhao, J., Chen, Q., Li, H., Myerburg, M., Spannhake, E.W., Natarajan, V., Zhao, Y., Lysophosphatidic acid increases soluble ST2 expression in mouse lung and human bronchial epithelial cells. Cell. Signal. 24:1 (2012), 77–85.
31. Sanada, S., Hakuno, D., Higgins, L.J., Schreiter, E.R., McKenzie, A.N., Lee, R.T., IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117:6 (2007), 1538–1549.
32. Chen, W.Y., Hong, J., Gannon, J., Kakkar, R., Lee, R.T., Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33. Proceedings of the National Academy of Sciences of the United States of America 112:23 (2015), 7249–7254.
33. Yanagisawa, K., Takagi, T., Tsukamoto, T., Tetsuka, T., Tominaga, S., Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett. 318:1 (1993), 83–87.
34. Iwahana, H., Yanagisawa, K., Ito-Kosaka, A., Kuroiwa, K., Tago, K., Komatsu, N., Katashima, R., Itakura, M., Tominaga, S., Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur. J. Biochem. 264:2 (1999), 397–406.
35. Iwahana, H., Hayakawa, M., Kuroiwa, K., Tago, K., Yanagisawa, K., Noji, S., Tominaga, S., Molecular cloning of the chicken ST2 gene and a novel variant form of the ST2 gene product, ST2LV. Biochem. Biophys. Acta. 1681:1 (2004), 1–14.
36. Tominaga, S., Kuroiwa, K., Tago, K., Iwahana, H., Yanagisawa, K., Komatsu, N., Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem. Biophys. Res. Commun. 264:1 (1999), 14–18.
37. Tago, K., Noda, T., Hayakawa, M., Iwahana, H., Yanagisawa, K., Yashiro, T., Tominaga, S., Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem. Biophys. Res. Commun. 285:5 (2001), 1377–1383.
38. Lingel, A., Weiss, T.M., Niebuhr, M., Pan, B., Appleton, B.A., Wiesmann, C., Bazan, J.F., Fairbrother, W.J., Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors–insight into heterotrimeric IL-1 signaling complexes. Structure 17:10 (2009), 1398–1410.
39. Palmer, G., Lipsky, B.P., Smithgall, M.D., Meininger, D., Siu, S., Talabot-Ayer, D., Gabay, C., Smith, D.E., The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 42:3 (2008), 358–364.
40. Liu, X., Hammel, M., He, Y., Tainer, J.A., Jeng, U.S., Zhang, L., Wang, S., Wang, X., Structural insights into the interaction of IL-33 with its receptors. Proceedings of the National Academy of Sciences of the United States of America 110:37 (2013), 14918–14923.
41. Chackerian, A.A., Oldham, E.R., Murphy, E.E., Schmitz, J., Pflanz, S., Kastelein, R.A., IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 179:4 (2007), 2551–2555.
42. Ali, S., Huber, M., Kollewe, C., Bischoff, S.C., Falk, W., Martin, M.U., IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proceedings of the National Academy of Sciences of the United States of America 104:47 (2007), 18660–18665.
43. Numata, T., Ito, T., Maeda, T., Egusa, C., Tsuboi, R., IL-33 promotes ICAM-1 expression via NF-kB in murine mast cells. Allergol. Int. 65:2 (2016), 158–165.
44. Cayrol, C., Girard, J.P., The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proceedings of the National Academy of Sciences of the United States of America 106:22 (2009), 9021–9026.
45. Luthi, A.U., Cullen, S.P., McNeela, E.A., Duriez, P.J., Afonina, I.S., Sheridan, C., Brumatti, G., Taylor, R.C., Kersse, K., Vandenabeele, P., Lavelle, E.C., Martin, S.J., Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31:1 (2009), 84–98.
46. Cohen, E.S., Scott, I.C., Majithiya, J.B., Rapley, L., Kemp, B.P., England, E., Rees, D.G., Overed-Sayer, C.L., Woods, J., Bond, N.J., Veyssier, C.S., Embrey, K.J., Sims, D.A., Snaith, M.R., Vousden, K.A., Strain, M.D., Chan, D.T., Carmen, S., Huntington, C.E., Flavell, L., Xu, J., Popovic, B., Brightling, C.E., Vaughan, T.J., Butler, R., Lowe, D.C., Higazi, D.R., Corkill, D.J., May, R.D., Sleeman, M.A., Mustelin, T., Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat. Commun., 6, 2015, 8327.
47. Bae, S., Kang, T., Hong, J., Lee, S., Choi, J., Jhun, H., Kwak, A., Hong, K., Kim, E., Jo, S., Kim, S., Contradictory functions (activation/termination) of neutrophil proteinase 3 enzyme (PR3) in interleukin-33 biological activity. J. Biol. Chem. 287:11 (2012), 8205–8213.
48. Zhao, J., Wei, J., Mialki, R.K., Mallampalli, D.F., Chen, B.B., Coon, T., Zou, C., Mallampalli, R.K., Zhao, Y., F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation. Nat. Immunol. 13:7 (2012), 651–658.
49. Bulek, K., Swaidani, S., Qin, J., Lu, Y., Gulen, M.F., Herjan, T., Min, B., Kastelein, R.A., Aronica, M., Kosz-Vnenchak, M., Li, X., The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J. Immunol. 182:5 (2009), 2601–2609.
50. Oshikawa, K., Yanagisawa, K., Tominaga, S., Sugiyama, Y., ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochem. Biophys. Res. Commun. 299:1 (2002), 18–24.
51. Reichenbach, D.K., Schwarze, V., Matta, B.M., Tkachev, V., Lieberknecht, E., Liu, Q., Koehn, B.H., Pfeifer, D., Taylor, P.A., Prinz, G., Dierbach, H., Stickel, N., Beck, Y., Warncke, M., Junt, T., Schmitt-Graeff, A., Nakae, S., Follo, M., Wertheimer, T., Schwab, L., Devlin, J., Watkins, S.C., Duyster, J., Ferrara, J.L., Turnquist, H.R., Zeiser, R., Blazar, B.R., The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood 125:20 (2015), 3183–3192.
52. Pastorelli, L., Garg, R.R., Hoang, S.B., Spina, L., Mattioli, B., Scarpa, M., Fiocchi, C., Vecchi, M., Pizarro, T.T., Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc. Natl. Acad. Sci. USA 107:17 (2010), 8017–8022.
53. Mehraj, V., Jenabian, M.A., Ponte, R., Lebouche, B., Costiniuk, C., Thomas, R., Baril, J.G., LeBlanc, R., Cox, J., Tremblay, C., Routy, J.P., t.C.L.-T.N.-P.S.G. Montreal primary Hiv Infection, the plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infection. Aids 30:10 (2016), 1617–1627.
54. Turner, J.R., Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 9:11 (2009), 799–809.
55. Mahapatro, M., Foersch, S., Hefele, M., He, G.-W., Giner-Ventura, E., McHedlidze, T., Kindermann, M., Vetrano, S., Danese, S., Günther, C., Neurath, Markus F., Wirtz, S., Becker, C., Programming of intestinal epithelial differentiation by IL-33 derived from pericryptal fibroblasts in response to systemic infection. Cell Rep. 15:8 (2016), 1743–1756.
56. Monticelli, L.A., Osborne, L.C., Noti, M., Tran, S.V., Zaiss, D.M.W., Artis, D., IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin–EGFR interactions. Proc. Natl. Acad. Sci. 112:34 (2015), 10762–10767.
57. Annunziato, F., Romagnani, C., Romagnani, S., The 3 major types of innate and adaptive cell-mediated effector immunity. J. Allergy Clin. Immunol. 135:3 (2015), 626–635.
58. Wynn, T.A., Type 2 cytokines: mechanisms and therapeutic strategies. Nat. Rev. Immunol. 15:5 (2015), 271–282.
59. Moro, K., Yamada, T., Tanabe, M., Takeuchi, T., Ikawa, T., Kawamoto, H., Furusawa, J.-I., Ohtani, M., Fujii, H., Koyasu, S., Innate production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells. Nature 463:7280 (2010), 540–544.
60. Price, A.E., Liang, H.E., Sullivan, B.M., Reinhardt, R.L., Eisley, C.J., Erle, D.J., Locksley, R.M., Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proceedings of the National Academy of Sciences of the United States of America 107:25 (2010), 11489–11494.
61. Neill, D.R., Wong, S.H., Bellosi, A., Flynn, R.J., Daly, M., Langford, T.K., Bucks, C., Kane, C.M., Fallon, P.G., Pannell, R., Jolin, H.E., McKenzie, A.N., Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464:7293 (2010), 1367–1370.
62. Oboki, K., Ohno, T., Kajiwara, N., Arae, K., Morita, H., Ishii, A., Nambu, A., Abe, T., Kiyonari, H., Matsumoto, K., Sudo, K., Okumura, K., Saito, H., Nakae, S., IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl. Acad. Sci. USA 107:43 (2010), 18581–18586.
63. Klose, C.S., Artis, D., Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat. Immunol. 17:7 (2016), 765–774.
64. Monticelli, L.A., Sonnenberg, G.F., Abt, M.C., Alenghat, T., Ziegler, C.G., Doering, T.A., Angelosanto, J.M., Laidlaw, B.J., Yang, C.Y., Sathaliyawala, T., Kubota, M., Turner, D., Diamond, J.M., Goldrath, A.W., Farber, D.L., Collman, R.G., Wherry, E.J., Artis, D., Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat. Immunol. 12:11 (2011), 1045–1054.
65. Zaiss, D.M., Yang, L., Shah, P.R., Kobie, J.J., Urban, J.F., Mosmann, T.R., Amphiregulin, a TH2 cytokine enhancing resistance to nematodes. Science, 314(5806), 2006, 1746.
66. Lopetuso, L.R., Scaldaferri, F., Pizarro, T.T., Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair, 5(1), 2012, 18.
67. Yan, F., Cao, H., Cover, T.L., Washington, M.K., Shi, Y., Liu, L., Chaturvedi, R., Peek, R.M. Jr., Wilson, K.T., Polk, D.B., Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J. Clin. Invest. 121:6 (2011), 2242–2253.
68. Sipos, F., Molnar, B., Zagoni, T., Berczi, L., Tulassay, Z., Growth in epithelial cell proliferation and apoptosis correlates specifically to the inflammation activity of inflammatory bowel diseases: ulcerative colitis shows specific p53- and EGFR expression alterations. Dis. Colon Rectum 48:4 (2005), 775–786.
69. Sipos, F., Muzes, G., Valcz, G., Galamb, O., Toth, K., Leiszter, K., Krenacs, T., Tulassay, Z., Molnar, B., Regeneration associated growth factor receptor and epithelial marker expression in lymphoid aggregates of ulcerative colitis. Scand. J. Gastroenterol. 45:4 (2010), 440–448.
70. Veiga-Fernandes, H., Pachnis, V., Neuroimmune regulation during intestinal development and homeostasis. Nat. Immunol. 18:2 (2017), 116–122.
71. Chow, A.K., Gulbransen, B.D., Potential roles of enteric glia in bridging neuroimmune communication in the gut. Am. J. Physiol. Gastr. Liver Physiol. 312:2 (2017), G145–G152.
72. Margolis, K.G., Gershon, M.D., Enteric neuronal regulation of intestinal inflammation. Trends Neurosci. 39:9 (2016), 614–624.
73. Powell, N., Walker, M.M., Talley, N.J., The mucosal immune system: master regulator of bidirectional gut-brain communications. Nat. Rev. Gastroenterol. Hepatol. 14:3 (2017), 143–159.
74. Sharkey, K.A., Emerging roles for enteric glia in gastrointestinal disorders. J. Clin. Invest. 125:3 (2015), 918–925.
75. Turco, F., Sarnelli, G., Cirillo, C., Palumbo, I., De Giorgi, F., D'Alessandro, A., Cammarota, M., Giuliano, M., Cuomo, R., Enteroglial-derived S100B protein integrates bacteria-induced toll-like receptor signalling in human enteric glial cells. Gut 63:1 (2014), 105–115.
76. Ibiza, S., Garcia-Cassani, B., Ribeiro, H., Carvalho, T., Almeida, L., Marques, R., Misic, A.M., Bartow-McKenney, C., Larson, D.M., Pavan, W.J., Eberl, G., Grice, E.A., Veiga-Fernandes, H., Glial-cell-derived neuroregulators control type 3 innate lymphoid cells and gut defence. Nature 535:7612 (2016), 440–443.
77. Zhang, D.K., He, F.Q., Li, T.K., Pang, X.H., Cui, D.J., Xie, Q., Huang, X.L., Gan, H.T., Glial-derived neurotrophic factor regulates intestinal epithelial barrier function and inflammation and is therapeutic for murine colitis. J. Pathol. 222:2 (2010), 213–222.
78. Meir, M., Flemming, S., Burkard, N., Bergauer, L., Metzger, M., Germer, C.T., Schlegel, N., Glial cell line-derived neurotrophic factor promotes barrier maturation and wound healing in intestinal epithelial cells in vitro. Am. J. Physiol. Gastrointest. Liver Physiol. 309:8 (2015), G613–G624.
79. Zhao, A., McDermott, J., Urban, J.F. Jr., Gause, W., Madden, K.B., Yeung, K.A., Morris, S.C., Finkelman, F.D., Shea-Donohue, T., Dependence of IL-4, IL-13, and nematode-induced alterations in murine small intestinal smooth muscle contractility on Stat6 and enteric nerves. J. Immunol. 171:2 (2003), 948–954.
80. Oh, J.E., Kim, B.C., Chang, D.H., Kwon, M., Lee, S.Y., Kang, D., Kim, J.Y., Hwang, I., Yu, J.W., Nakae, S., Lee, H.K., Dysbiosis-induced IL-33 contributes to impaired antiviral immunity in the genital mucosa. Proceedings of the National Academy of Sciences of the United States of America 113:6 (2016), E762–E771.
81. Belkaid, Y., Hand, T.W., Role of the microbiota in immunity and inflammation. Cell 157:1 (2014), 121–141.
82. Belkaid, Y., Harrison, O.J., Homeostatic immunity and the microbiota. Immunity 46:4 (2017), 562–576.
83. Thaiss, C.A., Zmora, N., Levy, M., Elinav, E., The microbiome and innate immunity. Nature 535:7610 (2016), 65–74.
84. van den Elsen, L.W., Poyntz, H.C., Weyrich, L.S., Young, W., Forbes-Blom, E.E., Embracing the gut microbiota: the new frontier for inflammatory and infectious diseases. Clin. Transl. Immunol., 6(1), 2017, e125.
85. Levy, M., Kolodziejczyk, A.A., Thaiss, C.A., Elinav, E., Dysbiosis and the immune system. Nat. Rev. Immunol. 17:4 (2017), 219–232.
86. Malik, A., Sharma, D., Zhu, Q., Karki, R., Guy, C.S., Vogel, P., Kanneganti, T.-D., IL-33 regulates the IgA-microbiota axis to restrain IL-1α-dependent colitis and tumorigenesis. J. Clin. Invest. 126:12 (2016), 4469–4481.
87. Palm, N.W., de Zoete, M.R., Cullen, T.W., Barry, N.A., Stefanowski, J., Hao, L., Degnan, P.H., Hu, J., Peter, I., Zhang, W., Ruggiero, E., Cho, J.H., Goodman, A.L., Flavell, R.A., Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 158:5 (2014), 1000–1010.
88. Stephens, W.Z., Round, J.L., IgA targets the troublemakers. Cell Host Microbe 16:3 (2014), 265–267.
89. Zaiss, M.M., Maslowski, K.M., Mosconi, I., Guenat, N., Marsland, B.J., Harris, N.L., IL-1β suppresses innate IL-25 and IL-33 production and maintains helminth chronicity. PLOS Pathogens, 9(8), 2013, e1003531.
90. Xu, D., Chan, W.L., Leung, B.P., Huang, F., Wheeler, R., Piedrafita, D., Robinson, J.H., Liew, F.Y., Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J. Exp. Med. 187:5 (1998), 787–794.
91. Guo, L., Wei, G., Zhu, J., Liao, W., Leonard, W.J., Zhao, K., Paul, W., IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proceedings of the National Academy of Sciences of the United States of America 106:32 (2009), 13463–13468.
92. Rank, M.A., Kobayashi, T., Kozaki, H., Bartemes, K.R., Squillace, D.L., Kita, H., IL-33-activated dendritic cells induce an atypical TH2-type response. J. Allergy Clin. Immunol. 123:5 (2009), 1047–1054.
93. Hussaarts, L., Yazdanbakhsh, M., Guigas, B., Priming dendritic cells for th2 polarization: lessons learned from helminths and implications for metabolic disorders. Front. Immunol., 5, 2014, 499.
94. Hung, L.Y., Lewkowich, I.P., Dawson, L.A., Downey, J., Yang, Y., Smith, D.E., Herbert, D.R., IL-33 drives biphasic IL-13 production for noncanonical Type 2 immunity against hookworms. Proceedings of the National Academy of Sciences of the United States of America 110:1 (2013), 282–287.
95. Wilson, S., Jones, F.M., Fofana, H.K., Landoure, A., Kimani, G., Mwatha, J.K., Sacko, M., Vennervald, B.J., Dunne, D.W., A late IL-33 response after exposure to Schistosoma haematobium antigen is associated with an up-regulation of IL-13 in human eosinophils. Parasite Immunol. 35:7–8 (2013), 224–228.
96. Licona-Limon, P., Kim, L.K., Palm, N.W., Flavell, R.A., TH2, allergy and group 2 innate lymphoid cells. Nat. Immunol. 14:6 (2013), 536–542.
97. Barlow, J.L., Peel, S., Fox, J., Panova, V., Hardman, C.S., Camelo, A., Bucks, C., Wu, X., Kane, C.M., Neill, D.R., Flynn, R.J., Sayers, I., Hall, I.P., McKenzie, A.N., IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J. Allergy Clin. Immunol. 132:4 (2013), 933–941.
98. Halim, T.Y., Krauss, R.H., Sun, A.C., Takei, F., Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 36:3 (2012), 451–463.
99. Omenetti, S., Pizarro, T.T., The Treg/Th17 Axis: a dynamic balance regulated by the gut microbiome. Front. Immunol., 6, 2015, 639.
100. Luo, A., Leach, S.T., Barres, R., Hesson, L.B., Grimm, M.C., Simar, D., The microbiota and epigenetic regulation of T helper 17/regulatory T cells in search of a balanced immune system. Front. Immunol., 8, 2017, 417.
101. Curotto de Lafaille, M.A., Lafaille, J.J., Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?. Immunity 30:5 (2009), 626–635.
102. Weaver, C.T., Hatton, R.D., Mangan, P.R., Harrington, L.E., IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annual Rev. Immunol. 25 (2007), 821–852.
103. Littman, D.R., Rudensky, A.Y., Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140:6 (2010), 845–858.
104. Ahern, P.P., Izcue, A., Maloy, K.J., Powrie, F., The interleukin-23 axis in intestinal inflammation. Immunol. Rev. 226 (2008), 147–159.
105. Cua, D.J., Sherlock, J., Chen, Y., Murphy, C.A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., Zurawski, S., Wiekowski, M., Lira, S.A., Gorman, D., Kastelein, R.A., Sedgwick, J.D., Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421:6924 (2003), 744–748.
106. Mazmanian, S.K., Round, J.L., Kasper, D.L., A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453:7195 (2008), 620–625.
107. Ivanov II, Atarashi, K., Manel, N., Brodie, E.L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K.C., Santee, C.A., Lynch, S.V., Tanoue, T., Imaoka, A., Itoh, K., Takeda, K., Umesaki, Y., Honda, K., Littman, D.R., Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139:3 (2009), 485–498.
108. Gaboriau-Routhiau, V., Rakotobe, S., Lecuyer, E., Mulder, I., Lan, A., Bridonneau, C., Rochet, V., Pisi, A., De Paepe, M., Brandi, G., Eberl, G., Snel, J., Kelly, D., Cerf-Bensussan, N., The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 31:4 (2009), 677–689.
109. Salzman, N.H., Hung, K., Haribhai, D., Chu, H., Karlsson-Sjoberg, J., Amir, E., Teggatz, P., Barman, M., Hayward, M., Eastwood, D., Stoel, M., Zhou, Y., Sodergren, E., Weinstock, G.M., Bevins, C.L., Williams, C.B., Bos, N.A., Enteric defensins are essential regulators of intestinal microbial ecology. Nat. Immunol. 11:1 (2010), 76–83.
110. Pascual-Reguant, A., Bayat Sarmadi, J., Baumann, C., Noster, R., Cirera-Salinas, D., Curato, C., Pelczar, P., Huber, S., Zielinski, C.E., Lohning, M., Hauser, A.E., Esplugues, E., TH17 cells express ST2 and are controlled by the alarmin IL-33 in the small intestine. Mucosal Immunol., 2017.
111. Schiering, C., Krausgruber, T., Chomka, A., Frohlich, A., Adelmann, K., Wohlfert, E.A., Pott, J., Griseri, T., Bollrath, J., Hegazy, A.N., Harrison, O.J., Owens, B.M.J., Lohning, M., Belkaid, Y., Fallon, P.G., Powrie, F., The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513:7519 (2014), 564–568.
112. Nascimento, D.C., Melo, P.H., Pineros, A.R., Ferreira, R.G., Colon, D.F., Donate, P.B., Castanheira, F.V., Gozzi, A., Czaikoski, P.G., Niedbala, W., Borges, M.C., Zamboni, D.S., Liew, F.Y., Cunha, F.Q., Alves-Filho, J.C., IL-33 contributes to sepsis-induced long-term immunosuppression by expanding the regulatory T cell population. Nat. Commun., 8, 2017, 14919.
113. Neurath, M.F., Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 14:5 (2014), 329–342.
114. Muzes, G., Molnar, B., Tulassay, Z., Sipos, F., Changes of the cytokine profile in inflammatory bowel diseases. World J. Gastroenterol. 18:41 (2012), 5848–5861.
115. Nemeth, Z.H., Bogdanovski, D.A., Barratt-Stopper, P., Paglinco, S.R., Antonioli, L., Rolandelli, R.H., Crohn's disease and ulcerative colitis show unique cytokine profiles. Cureus, 9(4), 2017, e1177.
116. Gundersen, M.D., Goll, R., Hol, J., Olsen, T., Rismo, R., Sorbye, S.W., Sundnes, O., Haraldsen, G., Florholmen, J., Loss of interleukin 33 expression in colonic crypts – a potential marker for disease remission in ulcerative colitis. Sci. Rep., 6, 2016, 35403.
117. Kobori, A., Yagi, Y., Imaeda, H., Ban, H., Bamba, S., Tsujikawa, T., Saito, Y., Fujiyama, Y., Andoh, A., Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J. Gastroenterol. 45:10 (2010), 999–1007.
118. Seidelin, J.B., IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol. Lett. 128 (2010), 80–85.
119. Sponheim, J., Pollheimer, J., Olsen, T., Balogh, J., Hammarstrom, C., Loos, T., Kasprzycka, M., Sorensen, D.R., Nilsen, H.R., Kuchler, A.M., Vatn, M.H., Haraldsen, G., Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am. J. Pathol. 177:6 (2010), 2804–2815.
120. Beltran, C.J., Nunez, L.E., Diaz-Jimenez, D., Farfan, N., Candia, E., Heine, C., Lopez, F., Gonzalez, M.J., Quera, R., Hermoso, M.A., Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 16:7 (2010), 1097–1107.
121. Latiano, A., Palmieri, O., Pastorelli, L., Vecchi, M., Pizarro, T.T., Bossa, F., Merla, G., Augello, B., Latiano, T., Corritore, G., Settesoldi, A., Valvano, M.R., D'Inca, R., Stronati, L., Annese, V., Andriulli, A., Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS One, 8(4), 2013, e62144.
122. Diaz-Jimenez, D., De la Fuente, M., Dubois-Camacho, K., Landskron, G., Fuentes, J., Perez, T., Gonzalez, M.J., Simian, D., Hermoso, M.A., Quera, R., Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution. BMC Gastroenterol, 16, 2016, 103.
123. Boga, S., Alkim, H., Koksal, A.R., Ozagari, A.A., Bayram, M., Tekin Neijmann, S., Sen, I., Alkim, C., Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity. J. Investig. Med. 64:5 (2016), 1016–1024.
124. Sedhom, M.A., Pichery, M., Murdoch, J.R., Foligne, B., Ortega, N., Normand, S., Mertz, K., Sanmugalingam, D., Brault, L., Grandjean, T., Lefrancais, E., Fallon, P.G., Quesniaux, V., Peyrin-Biroulet, L., Cathomas, G., Junt, T., Chamaillard, M., Girard, J.P., Ryffel, B., Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut 62:12 (2013), 1714–1723.
125. Pushparaj, P.N., Li, D., Komai-Koma, M., Guabiraba, R., Alexander, J., McSharry, C., Xu, D., Interleukin-33 exacerbates acute colitis via interleukin-4 in mice. Immunology 140:1 (2013), 70–77.
126. Seidelin, J.B., Coskun, M., Kvist, P.H., Holm, T.L., Holgersen, K., Nielsen, O.H., IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis. J. Gastroenterol. 50:2 (2015), 180–190.
127. Zhu, J., Xu, Y., Zhu, C., Zhao, J., Meng, X., Chen, S., Wang, T., Li, X., Zhang, L., Lu, C., Liu, H., Sun, X., IL-33 induces both regulatory B cells and regulatory T cells in dextran sulfate sodium-induced colitis. Int. Immunopharmacol. 46 (2017), 38–47.
128. Zhu, J., Yang, F., Sang, L., Zhai, J., Zhang, X., Yue, D., Li, S., Li, Y., Lu, C., Sun, X., IL-33 aggravates DSS-induced acute colitis in mouse colon lamina propria by enhancing Th2 cell responses. Mediators Inflamm., 2015, 2015, 913041.
129. Grobeta, P., Doser, K., Falk, W., Obermeier, F., Hofmann, C., IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm. Bowel Dis. 18:10 (2012), 1900–1909.
130. Duan, L., Chen, J., Zhang, H., Yang, H., Zhu, P., Xiong, A., Xia, Q., Zheng, F., Tan, Z., Gong, F., Fang, M., IL-33 ameliorates experimental colitis through promoting Th2/Foxp3(+) Treg responses in mice. Mol. Med., 18, 2012.
131. Tu, L., Chen, J., Xu, D., Xie, Z., Yu, B., Tao, Y., Shi, G., Duan, L., IL-33-induced alternatively activated macrophage attenuates the development of TNBS-induced colitis. Oncotarget, 2017.
132. Seo, D.H., Che, X., Kwak, M.S., Kim, S., Kim, J.H., Ma, H.W., Kim, D.H., Kim, T.I., Kim, W.H., Kim, S.W., Cheon, J.H., Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease. Sci. Rep., 7(1), 2017, 851.